<DOC>
	<DOC>NCT00468728</DOC>
	<brief_summary>This is a comparative study to investigate the safety and efficacy of PAR-101/OPT-80 (fidaxomicin) versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD).</brief_summary>
	<brief_title>PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)</brief_title>
	<detailed_description>The primary objective of this pivotal study is to investigate the safety and efficacy of PAR-101/OPT-80 versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD). The cure rates at end of therapy and recurrence rates will be evaluated and compared.</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Clostridium Infections</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>Males/females with CDAD Females must use adequate contraception Signed informed consent Lifethreatening CDAD Toxic megacolon Pregnant Concurrent use of diarrheal agents Participation in other trials</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>CDAD, Clostridium difficile, diarrhea</keyword>
	<keyword>Clostridium difficile-Associated Diarrhea</keyword>
</DOC>